GeoVax Labs, Inc. — Q2 2019 Form 10-Q
Reporting period: Three and six months ended June 30, 2019. GeoVax is a clinical-stage biotechnology company developing vaccines and immunotherapies; it reported no product sales. Its revenue came from government grants and research collaborations.
Financial performance and liquidity
| Metric | Q2 2019 | Q2 2018 | Six months 2019 | Six months 2018 |
|---|---|---|---|---|
| Grant and collaboration revenue | $209,941 | $93,265 | $574,173 | $314,564 |
| Research and development expense | $451,227 | $372,202 | $1,006,945 | $859,196 |
| General and administrative expense | $412,650 | $359,197 | $922,714 | $716,425 |
| Operating loss | $(653,936) | $(638,134) | $(1,355,486) | $(1,261,057) |
| Net loss | $(654,148) | $(637,043) | $(1,355,602) | $(1,258,856) |
| Basic and diluted loss per share | $(1.01) | $(2.05) | $(2.37) | $(4.50) |
At June 30, cash and cash equivalents were $216,411, versus $259,701 at year-end 2018. Total assets were $342,633 and total liabilities were $1,671,266; stockholders’ equity was negative $1,328,633. Working capital was in deficit by $1,319,179. Six-month operating cash use was $773,809, investing cash use $4,272, and financing cash provided $734,791, leaving cash down $43,290 from year-end. No gross margin is reported; the company had no product revenue.
Notes payable totaled $44,791, including $12,500 current and $32,291 long-term. Accrued expenses were $1,510,268, including $1,489,895 in deferred management salaries and directors’ fees. The company reported $459,000 of vendor and subcontractor purchase commitments, expected to be reimbursed under grants.
Changes from the prior comparable periods
- Revenue increased to $209,941 from $93,265 for Q2 and to $574,173 from $314,564 for the first half, primarily reflecting higher grant activity and collaboration revenue.
- First-half R&D expense rose about 17%, mainly due to the timing of grant-related expenditures; first-half G&A expense increased to $922,714 from $716,425, primarily due to legal fees, insurance, and costs of a special stockholder meeting.
- First-half net loss widened to $1,355,602 from $1,258,856. The lower reported loss per share compared with 2018 should be considered alongside the substantially higher weighted-average share count and the retroactive restatement for the one-for-500 reverse stock split.
- Financing cash included $740,000 in net proceeds from Series G preferred stock. The company also exchanged prior preferred shares for Series F preferred stock and converted preferred shares into common stock.
Outlook, risks and notable items
- Going concern: Management said cash resources, government funding commitments, clinical-trial support, and financing received after quarter-end were expected to fund planned operations into the first quarter of 2020. The filing nevertheless states that substantial doubt about the company’s ability to continue as a going concern remains. Additional capital is required, and may not be available on favorable terms or at all; absent funding, programs or overhead may need to be reduced.
- At June 30, approved grant funds available for 2019 and 2020 totaled $2,049,990; $1,219,066 was expected to reimburse third parties. Funding is tied to eligible activity and does not represent unrestricted cash.
- After quarter-end, holders exchanged Series F and G preferred stock for 3,257 Series H shares. GeoVax also agreed to sell 700 Series I preferred shares for $700,000 gross proceeds. Series H and I conversion prices are subject to a formula based on 80% of recent VWAP, with price-adjustment provisions; these terms and subsequent conversions could materially dilute common shareholders. The filing reports conversions and additional common shares issued for services during July and August.
- The company’s development programs include HIV, hemorrhagic fever viruses, Zika, malaria, hepatitis B, and cancers. Management described planned HIV studies, including a trial expected to begin enrollment in 2020, and an AGT collaboration trial expected to begin in late 2019; timing is uncertain. GeoVax cautioned that it cannot reliably estimate program costs or completion timelines.
- The common stock underwent a one-for-500 reverse split effective April 30, 2019. Management said it was intended to improve marketability and support financing or potential Nasdaq listing requirements; there is no assurance minimum listing price requirements will be met.
- The office and laboratory lease runs through December 31, 2019, with extension options; management intended to exercise at least the next one-year option, subject to the landlord’s cancellation right. The filing reported no legal proceedings and no material change in internal control over financial reporting.
Key facts for investors to verify
- Current cash runway, actual post-quarter financing proceeds, and progress toward raising capital beyond the first quarter of 2020.
- Terms, conversion activity, potential dilution, and any further price adjustments involving Series H and Series I preferred stock and related securities.
- Availability and reimbursement timing of grant funds, including the portion committed to third-party services.
- Status, funding, and timelines for the planned HIV trials and other development programs.
- Changes in deferred executive and director compensation, accrued liabilities, and the company’s going-concern assessment.